Your session is about to expire
← Back to Search
Cannabidiol for Chronic Liver Injury Prevention
Study Summary
This trial will look for possible long-term liver damage and scarring in people taking cannabidiol by mouth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 & 3 trial • 90 Patients • NCT04387617Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been on a stable non-drug therapy, like a special diet, for at least 4 weeks.I plan to undergo epilepsy or major surgery within the next five years.My liver function tests are significantly above normal levels.I am currently taking or will start taking Epidiolex for seizures.I am currently taking or will start taking Epidiolex for seizures.I have used cannabis or synthetic cannabinoid-based medications recently.I am not pregnant, breastfeeding, or planning to become pregnant during the study and for 3 months after.My liver is scarred, with a FibroScan score of 6.5 or higher.I am within the age range approved for this trial.
- Group 1: Cannabidiol
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any possible adverse effects to the application of Cannabidiol for therapeutic purposes?
"Backed by a Phase 4 trial, cannabidiol's safety is confidently assessed as 3 on our 1 to 3 scale."
What is the highest possible level of participation for this trial?
"Affirmative. As reported on clinicaltrials.gov, this research is still open for recruitment and began July 7th 2021. It has since been updated November 11th 2022, with a total of 150 participants to be enrolled at 29 distinct sites."
Are there any opportunities for enrolment into this trial currently available?
"Affirmative. Clinicaltrials.gov reveals that recruitment for this research project, first posted on July 7th 2021, is currently underway. 150 participants are being accepted from 29 different sites."
How widely dispersed are the experiments associated with this investigation throughout the state?
"This study is conducted across 29 different locations, including Wilmington, Richmond and Downey. To reduce travel burdens for participants, it's important to select the facility nearest you."
Are there any prior investigations of Cannabidiol's therapeutic potential?
"Currently, 79 trials exploring the efficacy of Cannabidiol are in progress. Of these studies, 16 have reached Phase 3 and there is a total of 290 sites across the globe recruiting patients to participate. The majority of clinical locations for this therapeutic agent are located in Ribeirao Preto, Sao Paulo."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Clinical Trial Site: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger